Poster abstracts
q8wks), ADA (80 mg wk 0, 40 mg wk 1, then 40 mg q2 wks),
or PBO (wks 0, 4, & 12, then GUS 100 mg wks 16 & 20). We
evaluated PROs using the Work Limitations Questionnaire [WLQ;
work productivity], the Hospital Anxiety & Depression Scale
[HADS], and the Medical Outcomes Study 36-Item Short Form
(SF-36; health related quality of life) at wk16 (GUS vs PBO) and
wk24 (GUS v s ADA) in pts with and without PsA.
Results: In all, 18% of pts reported a history of PsA. At wk16,
GUS pts had numerically greater improvements vs PBO in work
productivity, anxiety and depression, and SF-36 PCS & MCS
scores regardless of PsA status. The least square (LS) mean dif-
ferences (95% CI; adjusted for baseline value) for GUS vs PBO
for all PROs were generally similar between pts with and without
PsA. At wk24, GUS pts had numerically greater improvements
vs ADA in all PROs regardless of PsA status. The LS mean dif-
ferences for GUS vs ADA were generally greater for pts with PsA
vs pts without PsA (Table).
Conclusions: GUS showed better improvements in all PROs vs
PBO at wk16 and vs ADA at wk24. Improvements vs PBO were
similar regardless of PsA status, while improvements vs ADA
were greater for pts with PsA.
Table: Summary of Change from Baseline in WLQ, HADS and SF-36 Scores from
VOYAGE 2
Week 16 GUS vs PBO
w/ PSA
w/out PSA
N,
N,
LSMean
LSMean
Diff
Diff
(95%
(95%
CI)
p-value CI)
p-value
WLQ Physical 86, -7.1 0.0249 446, -7.7
Demands
(-13.21,
(-10.56,
-0.92)
-4.88)
85, -6.6 0.1326 419, -7.0
WLQ Time
Management (-15.35,
(-10.31,
2.06)
-3.79)
WLQ Mental- 83, -3.8 0.2913 439, -4.9
Interpersonal (-11.03,
(-7.54,
3.35)
-2.35)
WLQ Ouput 84, -7.9 0.0211 440, -3.5
Demands
(-14.51,
(-6.11,
-1.21)
-0.88)
135, -1.2 0.0584 608, -1.6
Anxiety
Score
(-2.45,
(-2.05,
0.04)
-1.07)
135, -1.2 0.0611 608, -1.5
Depression
Score
(-2.55,
(-1.96,
0.06)
-0.98)
SF-36 Physical 135, 5.7 < 0.0001 607, 4.4
Score
(2.94,
(3.31,
8.43)
5.39)
SF-36 Mental 135, 4.5 0.0026 607, 4.8
Score
(1.61,
(3.53,
7.48)
6.15)
N is the sample size across two groups.
Week 24 GUS vs ADA
w/ PSA
w/out PSA
N,
N,
LSMean
LSMean
Diff
Diff
(95%
p-
(95%
p-
CI)
value CI)
value
< 0.0001 79, -1.6
(-10.58,
7.29)
< 0.0001 79, -4.3
(-14.40,
5.81)
0.0002 78, -11.4
(-19.37,
-3.34)
0.0089 79, -14.7
(-24.29,
-5.17)
< 0.0001 133, -2.1
(-3.33,
-0.83)
< 0.0001 133, -1.5
(-2.85,
-0.09)
< 0.0001 132, 2.9
(0.21,
5.57)
< 0.0001 132, 3.2
(-0.12,
6.53)
0.7152 445, -2.6
(-5.39,
0.28)
0.3996 420, -0.6
(-3.46,
2.30)
0.0061 436, -1.5
(-4.16,
1.11)
0.0030 437, -1.2
(-3.94,
1.62)
0.0012 608, -0.8
(-1.29,
-0.28)
0.0374 608, -0.4
(-0.91,
0.10)
0.0346 608, 1.0
(-0.10,
2.04)
0.0591 608, 1.8
(0.45,
3.15)
0.0769
0.6931
0.2569
0.4136
0.0025
0.1158
0.0753
0.0092
P125
THE DERMATOLOGY LIFE QUALITY INDEX IN
RUSSIAN PATIENTS WITH PSORIASIS AND PSORIATIC
ARTHRITIS.
Nadezhda Batkaeva, Edgem Batkaev, Muslimat Gitinova
Peoples' Friendship University of Russia (RUDN University)
Introduction: The most severe form of psoriasis is psoriatic arthritis
(PsA), which belongs to the seronegative spondyloarthritis group,
characterized by chronic inflammation of the joints, spine, enthe-
sis. The frequency of PsA in the population is 0.06–1.4%. PSA is
comparable to rheumatoid arthritis (RA) in terms of progression,
disability and quality of life (QOL) in patients.
Objectives: Compare the quality of life index of patients with
severe forms of psoriasis (PsO) with psoriatic arthritis patients’
index.
Methods: 120 (100%) patients suffering from PsO and PsA
(Male-87/female - 33) were analyzed. 70 (54.2%) patients were
diagnosed PsO, 50 (41.7%) were diagnosed PsA. The average
age of patients with skin manifestations PsO was 54.0 ± 14.2 years
(n = 70). The average age of patients with PsA was 49.1 ± 15.9 years
51
(n = 50). The group of patients with PsA was older than the group
PsO patients by age. PASI > 10. The quality of life was assessed
using the Dermatology Life Quality Index (DLQI) questionnaire.
The results were evaluated: from 0 to 1 score - cutaneous disease
does not affect the patient's life, from 2 to 5 scores - the disease
has a minor effect on the patient's life, from 6 to 10 scores - the
disease has a moderate effect on the patient's life, from 11 to 20
scores - the disease has a very strong effect on the patient's life,
from 21 to 30 scores - the disease has an extremely strong effect
on the patient's life. Statistical processing of the data was carried
out using the Excel analysis package. All p < 0.05 were considered
to indicate statistical significance.
Results: 120 (100%) patients suffering from PsO were taken for
analysis. The duration of PsO was: for more than 15 years - 25
people (35.7%), 10–15 years - 18 people (25.7%); 3–10 years -
15 people (21.4%), 1–3 years - 12 people (17.1%). The duration
of PsA was: for more than 15 years – 5 people (10.0%), 10–15
years – 7 people (14.0%); 3–10 years – 20 people (40.0%), 1–3
years – 18 people (36.0%). Heredity was aggravated in 35 (29.1%)
out of 120 patients. Comorbidity was presented in 112 (93.3%) out
of 120 patients. Gastrointestinal and liver diseases were found in
48 (42.8%) out of 120 patients. Type 2 diabetes was observed in
45 (40.1%) out of 120 patients, cardiovascular diseases - in 100
(89.2%) out of 120 patients, diseases of the nervous system - in 59
(52.6%) out of 120 patients, and diseases of the urinary system - in
20 (17.8%) out of 120 patients.
The total score DLQI in the psoriasis group was 15.8 ± 5.2. The
score DLQI in PsO patients was 12.5 ± 3.4 and in PsA patients was
20.4 ± 3.7. The total score DLQI in PsO patients with comorbidity
was 16.1 ± 5.3.
Conclusions: The total score DLQI was significantly higher in
patients with PsA compare to PsO patients. This result revealed
the existence of an inferior quality of life for the PsO patients with
comorbidity disease, compared with pts without comorbidity di-
sease. The score of DLQI is affected the development and progress
of the psoriasis and comorbidity pathology. Then higher DLQI
value, the more it affects experience considerable physical and/
or psychological discomfort, difficulties in social and professional
adaptation, which subsequently cause significant distress and even
social phobia. All these conditions psoriasis are interrelated by
genetic and immunopathogenetic mechanisms. Thus, patients with
psoriasis require an integrated approach and dynamic observation
by dermatologists and doctors of related specialties.
P126
EFFECTS OF MINDFUL NESS-BASED COGNITIVE
THERAPY ON SELF-REPORTED PSORIASIS AND
PSYCHOLOGICAL SYMPTOMS
Alan Maddock, David Hevey
School of Psychology, Trinity College Dublin
Introduction: Psoriasis can have a profound impact on a patient’s
life, with the prevalence of anxiety, depression, poor wellbeing
and quality of life generally found to be high in psoriasis popula-
tions. Mindfulness based interventions have been shown to have
positive impacts on anxiety, depression, wellbeing and quality of
life in various populations.
Objectives: The aim of the present study was to investigate the ef-
fect of mindfulness-based cognitive therapy (MBCT) on psoriasis
symptoms and psychological symptoms associated with psoriasis
including anxiety, depression, reduced wellbeing and QoL. The
study also aimed to investigate if MBCT significantly impacted
the potential mediating variables of a new theory of mindfulness
mechanisms the ‘Clinically Modified Buddhist Psychological
Model (CBPM)’, these variables being acceptance, mindfulness,
self-compassion, aversion, non-attachment, attention, rumination
and worry.
Acta Derm Venereol 2018